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Despite its high prevalence, the mechanisms causing diabetic kidney disease remain poorly understood.
In this issue ofCell Metabolism, Welsh et al. (2010) show that elimination of insulin receptors from the glomer-
ular podocyte, a cell that is central to the pathogenesis of proteinuric renal diseases, recapitulates many
features of human diabetic nephropathy.Diabetic nephropathy (DN) is the leading
cause of incident end-stage renal disease
in the United States (U.S. Renal Data
System, USRDS 2007 Annual Data
Report, http://www.usrds.org). The ear-
liest clinically detectable sign of overt DN
is the excretion of high levels of protein in
the urine, indicating an abnormality in the
glomerular permeability barrier. This is fol-
lowed by progressive loss of glomerular
filtration rate (Fioretto and Mauer, 2007).
Kidneys from patients with DN are
typically enlarged, with large glomeruli
and thickened glomerular basement
membranes; nodular glomerular sclerosis
is the characteristic pathological feature.
Several large clinical trials, such as the
UKPDS (UK Prospective Diabetes Study)
and the ADVANCE (Action in Diabetes
and Vascular Disease: Preterax and Dia-
micron Modified Release Controlled Eval-
uation) trial, have shown that tight glyce-
mic control can prevent the development
of kidney disease. In established DN,
control of blood pressure and blockade
of the renin-angiotensin system can slow
progression, but therearenospecific ther-
apies for blocking or reversing kidney
injury (Gurley and Coffman, 2007). More-
over, the precise molecular pathogenesis
of this disorder has not been clearly
defined. Nonetheless, a number of factors
have been implicated, including reactive
oxygen species, advanced glycation end-
products, and enhanced levels of TGF-b
(Wolf et al., 2005). In this issue, Welsh
et al. (2010) suggest that impaired insulin
signaling in the glomerular podocyte may
be another critical mechanism leading
to DN.Although the characteristics of DN
are virtually indistinguishable in patients
with type 1 or type 2 diabetes, the role of
altered insulin signaling in specific cell
lineages in the kidney has not been widely
studied as a potential etiological mecha-
nism. Indeed, diabetic kidney disease
has long been considered to be a ‘‘micro-
vascular’’ complication of diabetes, and
endothelial dysfunction has been high-
lighted as a central causative factor (Jen-
sen et al., 1989). Recently, the importance
of such endothelial pathways has been
emphasized in attempts to develop ani-
mal models that more closely resemble
human DN (Brosius et al., 2009). In this
context, the findings of Welsh and col-
leagues (2010) may signal a pivotal
change in the field. Using an elegant
gene-targeting approach carried out
in collaboration with the Quaggin lab,
podIRKO mice were generated with cell-
specific deletion of insulin receptors from
glomerular epithelial cells, also known as
podocytes. While their kidneys are normal
at birth, podIRKO mice develop signifi-
cant proteinuria by 5 weeks of age and
with further aging develop some of
the abnormalities that are characteristic
of human DN, including effacement of
podocyte foot processes, accumulation
of mesangial matrix, thickening of the
glomerular basement membrane, and
glomerulosclerosis. Importantly, these
abnormalities developed in animals with
normal serum glucose levels. These find-
ings suggest that impaired insulin sig-
naling in the podocyte is sufficient to
affect normal functioning of the glomer-
ular filtration barrier and to induce someCell Metabolism 1of the pathological features of DN, all in
the absence of hyperglycemia (Figure 1).
While this discovery of a critical role for
insulin in the maintenance of glomerular
epithelial cell structure and function may
be viewed as surprising, a key role for
the podocyte in the pathogenesis of
DN is not. Several syndromes of familial
glomerulopathies are caused by muta-
tions that affect genes specifically ex-
pressed in the podocyte, including
nephrin (NPHS1) in Finnish nephropathy
and podocin (NPHS2) in steroid-resistant
nephrotic syndrome (Daskalakis and
Winn, 2006). Many of these familial disor-
ders are characterized by abnormalities
of the podocyte cytoskeleton where dys-
function of cytoskeletal proteins can lead
to foot process effacement and loss of
GBM integrity. In this regard, Welsh and
colleagues show that insulin receptor
activation triggers remodeling of the
podocyte cytoskeleton through activation
of MAPK and PI3K pathways. It follows
that in the absence of insulin signaling,
such functions may be impaired.
There is also clear evidence for a role of
the podocyte in DN. For example, efface-
ment of podocytes, attenuated expres-
sion of nephrin, and a reduction in podo-
cyte number have been observed in
animal models and patients with DN.
Since podocytes are terminally differenti-
ated cells, they cannot be effectively
replaced when lost from the glomerulus
through apoptosis or other mechanisms,
resulting in destabilization of the glomer-
ular tuft, leading to proteinuria and glo-
merulosclerosis (Wharram et al., 2005).
In fact, loss of podocytes is a strong2, October 6, 2010 ª2010 Elsevier Inc. 311
Figure 1. Impaired Insulin Receptor Signaling in Podocytes May
Promote the Development of Nephropathy through Two
Mechanisms
One pathway is through effects on cytoskeletal function. In the second
pathway, the absence of insulin receptor signaling may leave the podocyte
susceptible to apoptosis, which can cause proteinuria, instability of the
glomerular tuft, and sclerosis.
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Previewspredictor of progressive renal
disease in patients with dia-
betes (Meyer et al., 1999). In
the podIRKO animals, there
was exaggerated podocyte
apoptosis, suggesting that
the insulin receptor promotes
glomerular epithelial cell sur-
vival (Figure 1).
The investigations of Welsh
and associates provide com-
pelling evidence that insulin
signaling can regulate podo-
cyte structure and function
in vivo, but they also raise
a number of interesting issues
for further exploration and
clarification. For example,
while the podIRKO mice
develop kidney disease that
is reminiscent of DN, some
of the observed pathologi-
cal changes are relatively
nonspecific, and certain char-
acteristic features of DN such
as increased kidney size and
nodular glomerulosclerosis
are not present. This raises
the question of whether there
may be important actions of
insulin in other cell lineages,
in addition to the podocyte,
that modulate renal manifes-
tations of DN. Alternatively,
these may be controlled by
other factors that are inde-
pendent of insulin signaling
per se.
As discussed above, a
wealth of data from basic
studies and clinical trials
have implicated abnormali-
ties of the endothelium as a
key factor in the generation
of glomerular injury in dia-
betes. In diabetics, endothe-lial dysfunction has been correlated with
the development of microalbuminuria, a
harbinger of renal involvement in diabetes
that is also associated with enhanced
cardiovascular risk (Gerstein et al., 2001).
This raises the possibility of critical inter-
actions between an abnormal endothe-
lium and the insulin-resistant podocyte312 Cell Metabolism 12, October 6, 2010 ª20acting in concert to promote kidney injury
in diabetes. Only a fraction of diabetic
patients with microalbuminuria develop
overt DN. Perhaps the transition from mi-
croalbuminuria to a more advanced stage
of disease requires a podocyte abnor-
mality superimposed on the background
of diabetic endothelial dysfunction.10 Elsevier Inc.In conclusion, the study by
Welsh et al. (2010) has identi-
fied a potential role for insulin
signaling in podocyte func-
tion and survival, and loss of
this pathway may contribute
to the pathogenesis of DN.
Insulin resistance in podo-
cytes must now be added to
the list of suspects implicated
in the complex pathogenesis
of DN. Furthermore, these
data suggest that enhancing
insulin action in podocytes
and perhaps other renal cell
lineages may help prevent
development and progres-
sion of DN, a leading cause
of end-stage renal disease
world-wide.
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